Table 1.
Clinical characteristics of the study participants (n = 306).
| Variables | Total | TB-NCOPD | TB-COPD | P |
|---|---|---|---|---|
| (n = 306) | (n = 155) | (n = 151) | ||
| Gender, n (%) | .668 | |||
| Female | 108 (35.29) | 57 (36.77) | 51 (33.77) | |
| Male | 198 (64.71) | 98 (63.23) | 100 (66.23) | |
| Age, (yr) | 71 (68, 76) | 70 (67, 74) | 72 (68, 79) | .055 |
| Blood platelet count (BPC, 109/L) | 211.5 (158.25, 263.5) | 200 (154, 255.5) | 213 (162, 276) | .198 |
| Hemoglobin (g/L) | 118.62 ± 17.24 | 119.3 ± 17.12 | 117.92 ± 17.39 | .484 |
| Biochemical indexes | ||||
| Albumin (g/L) | 36.35 (32.52, 39.18) | 36.7 (33.2, 39.25) | 35.7 (31.4, 39.1) | .135 |
| Globulin (g/L) | 27.95 (24.33, 31.6) | 27.6 (24, 31.6) | 28.1 (24.75, 31.6) | .608 |
| A/G (ratio) | 1.31 ± .34 | 1.34 ± .35 | 1.28 ± .33 | .123 |
| Liver function | ||||
| Serum glutamic oxaloacetic transaminase (SGOT, U/L) | 21.1 (17.2, 27.1) | 21.5 (18.2, 27.1) | 2.5 (16.55, 27.65) | .163 |
| Serum glutamic pyruvic transaminase (SGPT, U/L) | 14 (1.12, 22.92) | 13.9 (1.25, 21.45) | 14.3 (9.75, 24.35) | .886 |
| Lactic acid dehydrogenase (LDH, U/L) | 190 (166, 216) | 189 (169, 214) | 190 (166, 22.5) | .839 |
| Total bilirubin (TBiL, µmol/L) | 12.2 (8.22, 17.62) | 12.6 (8.2, 18.65) | 12 (8.35, 16.8) | .404 |
| Direct bilirubin (DBiL, µmol/L) | 4.2 (2.62, 6.2) | 4.4 (2.6, 6.2) | 4.1 (2.7, 6.15) | .92 |
| CMV status | ||||
| CMV seropositive | 120 (39.22) | 50 (32.26) | 70 (46.36) | .03 |
| CMV seronegative | 186 (60.78) | 105 (67.74) | 81 (53.64) | |
The data was showed as (M ± SD), and A significance level of P < .05 was employed to determine statistical significance.
CMV = cytomegalovirus, COPD = chronic obstructive pulmonary disease, TB = tuberculosis, TB-COPD = TB patients with chronic obstructive pulmonary disease, TB-NCOPD = TB patients without chronic obstructive pulmonary disease.